Effectiveness and Safety of Vortioxetine for Major Depressive Disorder in Real-World Clinical Practice: Results from the Single-Arm RELIEVE China Study

References

• GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1789–1858. doi:10.1016/S0140-6736(18)32279-7
   PubMed Web of Science ®Google Scholar
• Moreno-Agostino D, Wu YT, Daskalopoulou C, Hasan MT, Huisman M, Prina M. Global trends in the prevalence and incidence of depression: a systematic review and meta-analysis. J Affect Disord. 2021;281:235–243. doi:10.1016/j.jad.2020.12.035
   PubMed Web of Science ®Google Scholar
• Huang Y, Wang Y, Wang H, et al. Prevalence of mental disorders in China: a cross-sectional epidemiological study. Lancet Psychiatry. 2019;6(3):211–224. doi:10.1016/s2215-0366(18)30511-x
   PubMed Web of Science ®Google Scholar
• Ma X, Li S, Xiang Y, et al. Survey on the prevalence of depression in Beijing. Chin J Psychiatry. 2007;40:100–103. doi:10.3760/j.issn:1006-7884.2007.02.009
   Google Scholar
• Zhao YJ, Jin Y, Rao WW, et al. Prevalence of major depressive disorder among adults in China: a systematic review and meta-analysis. Front Psychiatry. 2021;12:659470. doi:10.3389/fpsyt.2021.659470
   PubMed Web of Science ®Google Scholar
• Yang G, Wang Y, Zeng Y, et al. Rapid health transition in China, 1990–2010: findings from the Global Burden of Disease Study 2010. Lancet. 2013;381(9882):1987–2015. doi:10.1016/s0140-6736(13)61097-1
   PubMed Web of Science ®Google Scholar
• Lu J, Xu X, Huang Y, et al. Prevalence of depressive disorders and treatment in China: a cross-sectional epidemiological study. Lancet Psychiatry. 2021;8(11):981–990. doi:10.1016/s2215-0366(21)00251-0
   PubMed Web of Science ®Google Scholar
• Hu TW, He Y, Zhang M, Chen N. Economic costs of depression in China. Soc Psychiatry Psychiatr Epidemiol. 2007;42(2):110–116. doi:10.1007/s00127-006-0151-2
   PubMed Web of Science ®Google Scholar
• Li W, Yang Y, Liu Z-H, et al. The first national action plan on depression in China: progress and challenges. Lancet Reg Health West Pac. 2021;7:100078. doi:10.1016/j.lanwpc.2020.100078
   Google Scholar
• Chen Y, Bennett D, Clarke R, et al. Patterns and correlates of major depression in Chinese adults: a cross-sectional study of 0.5 million men and women. Psychol Med. 2017;47(5):958–970. doi:10.1017/S0033291716002889
   PubMed Web of Science ®Google Scholar
• Qi H, Zong QQ, Lok GKI, et al. Treatment rate for major depressive disorder in China: a meta-analysis of epidemiological studies. Psychiatr Q. 2019;90(4):883–895. doi:10.1007/s11126-019-09666-9
   Web of Science ®Google Scholar
• Ren X, Yu S, Dong W, Yin P, Xu X, Zhou M. Burden of depression in China, 1990–2017: findings from the global burden of disease study 2017. J Affect Disord. 2020;268:95–101. doi:10.1016/j.jad.2020.03.011
   PubMed Web of Science ®Google Scholar
• McKnight PE, Kashdan TB. The importance of functional impairment to mental health outcomes: a case for reassessing our goals in depression treatment research. Clin Psychol Rev. 2009;29(3):243–259. doi:10.1016/j.cpr.2009.01.005
   PubMed Web of Science ®Google Scholar
• Hu WM, Yin XY, Yin XL, et al. Prevalence, social-demographic and cognitive correlates of depression in Chinese psychiatric medical staff. J Affect Disord. 2020;263:60–63. doi:10.1016/j.jad.2019.11.133
   Web of Science ®Google Scholar
• McIntyre RS, Harrison J, Loft H, Jacobson W, Olsen CK. The effects of vortioxetine on cognitive function in patients with major depressive disorder: a meta-analysis of three randomized controlled trials. Int J Neuropsychopharmacol. 2016;19(10):pyw055. doi:10.1093/ijnp/pyw055
   PubMed Web of Science ®Google Scholar
• Conradi HJ, Ormel J, de Jonge P. Presence of individual (residual) symptoms during depressive episodes and periods of remission: a 3-year prospective study. Psychol Med. 2011;41(6):1165–1174. doi:10.1017/s0033291710001911
   PubMed Web of Science ®Google Scholar
• Harrison JE, Lophaven S, Olsen CK. Which cognitive domains are improved by treatment with vortioxetine? Int J Neuropsychopharmacol. 2016;19(10):pyw054. doi:10.1093/ijnp/pyw054
   Web of Science ®Google Scholar
• Wang R, Liu Y, Xue D, Helbich M. Depressive symptoms among Chinese residents: how are the natural, built, and social environments correlated? BMC Public Health. 2019;19(1):887. doi:10.1186/s12889-019-7171-9
   PubMed Web of Science ®Google Scholar
• Li L, Lok GKI, Mei SL, et al. Prevalence of depression and its relationship with quality of life among university students in Macau, Hong Kong and mainland China. Sci Rep. 2020;10(1):15798. doi:10.1038/s41598-020-72458-w
   Web of Science ®Google Scholar
• Wang G, Tan KHX, Ren H, Hammer-Helmich L. Impact of cognitive symptoms on health-related quality of life and work productivity in Chinese patients with major depressive disorder: results from the PROACT study. Neuropsychiatr Dis Treat. 2020;16:749–759. doi:10.2147/ndt.S230403
   Web of Science ®Google Scholar
• News Release. Takeda and Lundbeck announce Ministry of Health, Labour and Welfare (MHLW) approval of Trintellix® in Japan. Takeda Pharmaceutical Company Limited; 2019.
   Google Scholar
• Mahableshwarkar AR, Zajecka J, Jacobson W, Chen Y, Keefe RS. A randomized, placebo-controlled, active-reference, double-blind, flexible-dose study of the efficacy of vortioxetine on cognitive function in major depressive disorder. Neuropsychopharmacology. 2015;40(8):2025–2037. doi:10.1038/npp.2015.52
   PubMed Web of Science ®Google Scholar
• Katona C, Hansen T, Olsen CK. A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder. Int Clin Psychopharmacol. 2012;27(4):215–223. doi:10.1097/YIC.0b013e3283542457
   PubMed Web of Science ®Google Scholar
• McIntyre RS, Lophaven S, Olsen CK. A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults. Int J Neuropsychopharmacol. 2014;17(10):1557–1567. doi:10.1017/s1461145714000546
   PubMed Web of Science ®Google Scholar
• Iovieno N, Papakostas G, Feeney A, et al. Vortioxetine versus placebo for major depressive disorder: a comprehensive analysis of the clinical trial dataset. J Clin Psychiatry. 2021;82(4):20r13682. doi:10.4088/JCP.20r13682
   PubMed Web of Science ®Google Scholar
• Thase ME, Mahableshwarkar AR, Dragheim M, Loft H, Vieta E. A meta-analysis of randomized, placebo-controlled trials of vortioxetine for the treatment of major depressive disorder in adults. Eur Neuropsychopharmacol. 2016;26(6):979–993. doi:10.1016/j.euroneuro.2016.03.007
   PubMed Web of Science ®Google Scholar
• Florea I, Loft H, Danchenko N, et al. The effect of vortioxetine on overall patient functioning in patients with major depressive disorder. Brain Behav. 2017;7(3):e00622. doi:10.1002/brb3.622
   PubMed Web of Science ®Google Scholar
• Kennedy-Martin T, Curtis S, Faries D, Robinson S, Johnston J. A literature review on the representativeness of randomized controlled trial samples and implications for the external validity of trial results. Trials. 2015;16(1):495. doi:10.1186/s13063-015-1023-4
   PubMed Web of Science ®Google Scholar
• Han C, Pae C-U. Do we need to consider ethno-cultural variation in the use of atypical antipsychotics for Asian patients with major depressive disorder? CNS Drugs. 2013;27(1):47–51. doi:10.1007/s40263-012-0033-y
   Web of Science ®Google Scholar
• Jovanovic BD, Levy PS. A look at the rule of three. Am Stat. 1997;51(2):137–139. doi:10.1080/00031305.1997.10473947
   Web of Science ®Google Scholar
• Wang G, Gislum M, Filippov G, Montgomery S. Comparison of vortioxetine versus venlafaxine XR in adults in Asia with major depressive disorder: a randomized, double-blind study. Curr Med Res Opin. 2015;31(4):785–794. doi:10.1185/03007995.2015.1014028
   PubMed Web of Science ®Google Scholar
• Mattingly G, Ren H, Cronquist Christensen M, Simonsen K, Hammer-Helmich L. P.0724 Vortioxetine in routine clinical practice: results from the real-life effectiveness of vortioxetine (RELIEVE) study. Eur Neuropsychopharmacol. 2021;53(suppl1):S529–S530. doi:10.1016/j.euroneuro.2021.10.793
   Web of Science ®Google Scholar
• McIntyre RS, Cha DS, Soczynska JK, et al. Cognitive deficits and functional outcomes in major depressive disorder: determinants, substrates, and treatment interventions. Depress Anxiety. 2013;30(6):515–527. doi:10.1002/da.22063
   PubMed Web of Science ®Google Scholar
• Baldwin DS, Chrones L, Florea I, et al. The safety and tolerability of vortioxetine: analysis of data from randomized placebo-controlled trials and open-label extension studies. J Psychopharmacol. 2016;30(3):242–252. doi:10.1177/0269881116628440
   PubMed Web of Science ®Google Scholar
• Wang G, Ge H, Ma J, Hammer-Helmich L, Ren H. PMH9 Effectiveness of vortioxetine in daily practice in China. interim results from the real-life effectiveness of vortioxetine in China (RELIEVE China) study. Value Health. 2020;23(suppl2):S58. doi:10.1016/j.jval.2020.08.1087
   Google Scholar